SK Biopharm Introduces Epilepsy New Drug Candidate Worth ₩1.1 Trillion… First Trillion-Won Technology Acquisition in Korean Pharmaceutical and Bio Industry

It was pointed out that the company's external communication culture did not align with Korean sentiment, lacking concrete roadmaps or performance presentations that investors desired. In particular, disappointment was high as investors perceive Hyundai Motor as a physical AI company, yet no specific plans such as the IPO of Boston Dynamics were presented.

Peptron was cited as a prime example, where content presented at a forum was negatively interpreted by the market, leading to a significant drop in its stock price. This highlights the importance of corporate information disclosure methods and investor communication.

SK Biopharm has secured an epilepsy new drug candidate through a license-in, rather than license-out, model. This is the first technology acquisition deal worth over a trillion won by a Korean bio company, drawing attention with an upfront payment of ₩550 billion that is non-refundable. This agreement is being praised for setting a new milestone in the domestic bio industry.

The U.S. Treasury announced plans to use funds from its Treasury General Account (TGA) to purchase Treasury bonds. This is interpreted as a policy measure aimed at lowering bond yields. Market experts advise not to oppose the U.S. Treasury's policy intentions, predicting that various policy tools to lower bond yields will continuously emerge in the future.

News has emerged that the U.S. administration is preparing to redeploy diplomats to the Middle East. This raises the possibility of an agreement with Iran regarding passage through the Strait of Hormuz, interpreted as a positive signal that the potential for physical conflict in the Middle East may ease. The return of diplomats is seen as part of efforts to improve relations with Iran and stabilize the region.

Despite rumors that the U.S. government requested the Korean government to invest in Westinghouse, and official denials, market expectations persist. This reflects investors' belief in the potential for overseas export of Korean nuclear power plants and the materialization of cooperation with Westinghouse. Although denied, related issues are driving up the stock prices of nuclear power-related companies. This situation indicates increasing domestic and international interest in the nuclear power industry.

The market, operating under the sentiment of 'no smoke without fire,' continued to buy stocks, holding onto expectations for related issues. This is analyzed as reflecting investors' strong confidence in the government's energy policy direction and the growth of the nuclear power industry. Despite rumors, expectations for the potential of the nuclear power industry are positively influencing the market.

Ahead of Nvidia's earnings announcement, the market is experiencing a mix of anticipation and concern. The pattern of stock prices falling by 2-3% after earnings announcements has repeated for the past four quarters, raising the possibility of a similar trend this time. In particular, Nvidia's guidance expectations have significantly increased from $15 billion to $100 billion, sparking keen interest in whether it can meet these expectations. The revenue outlook for Rubin is also expected to have a significant impact on the stock prices of domestic semiconductor companies such as Samsung Electronics and SK Hynix.

How confidently Nvidia will forecast Rubin's shipment volume for next year is crucial, as it could directly impact the performance of domestic semiconductor companies. Additionally, if there are comments regarding the resumption of sales in China, it is expected to have a positive impact on the overall semiconductor market. High interest is focused on Nvidia's announcement, as it could determine the direction of domestic semiconductor companies' stock prices.

In particular, the GLP-2 analog contract with Eli Lilly and the urocorotin-2 technology transfer contract with Roche's subsidiary Genentech are cited as examples proving Hanmi Pharmaceutical's technological prowess. Based on these achievements, Hanmi Pharmaceutical is emerging as a key leader in the obesity treatment market.

It has successfully completed phase 3 clinical trials and is currently awaiting product approval from the Ministry of Food and Drug Safety, with a launch expected as early as October this year. This will be a significant turning point for Hanmi Pharmaceutical, overcoming past setbacks and pioneering a new obesity treatment market.

This analysis is based on the belief that the current stock price is excessively low compared to Hanmi Pharmaceutical's technological prowess and future growth potential.

This contract, with an upfront payment of ₩550 billion, is set to be recorded as an unprecedented large-scale technology acquisition in the history of the Korean pharmaceutical and bio industry. Through this agreement, SK Biopharm aims to proactively secure competitive new drug candidates and strengthen its dominance in the epilepsy treatment market. This bold investment is expected to positively impact the overall domestic bio industry.

This case demonstrates that the time has come for Korean bio companies to make bold investments to secure competitiveness in the global market. This agreement is expected to positively impact SK Biopharm's Xcopri sales outlook and serve as a crucial variable in the change of supply and demand trends for domestic pharmaceutical and bio companies.

This is a significant factor that enhances Ingenia Therapeutics' future growth potential, with even the possibility of reaching a market capitalization of ₩1 trillion being mentioned. As a newly listed stock, it is attracting significant market attention, and stock price volatility is expected to increase depending on the specific details of the technology transfer contract.

Investors should monitor these two major events and prepare for market volatility.